Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
A phase 2 trial of isunakinra in colorectal cancer, run by Buzzard Pharmaceuticals, now recruiting.
Overview
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) is a phase 2 interventional study registered as NCT06634875 by Buzzard Pharmaceuticals, with 20 participants planned, started 2025-01-30 and due to reach its primary completion in 2026-06. Interventions recorded: isunakinra.
Similar pages
not linked directly; found by shared links- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Clinical Study of Arfolitixorin in Patients With mCRC
Shares Colorectal cancer and the tag pipeline.
- TrialFirst-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.